{"log_id": 6534780498740175617, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0, "average": 0.99981, "min": 0.999239}, "location": {"width": 174, "top": 175, "height": 35, "left": 154}, "words": "乳糖耐受不良患者"}, {"probability": {"variance": 0.000608, "average": 0.993337, "min": 0.863042}, "location": {"width": 878, "top": 200, "height": 55, "left": 199}, "words": "本品含有乳糖。有罕见的遗传性半乳糖不耐受、Lapp乳糖酶缺乏或葡葡糖半乳糖吸收不良的患者"}, {"probability": {"variance": 0, "average": 0.999475, "min": 0.998957}, "location": {"width": 125, "top": 275, "height": 26, "left": 159}, "words": "不应使用本品"}, {"probability": {"variance": 3e-06, "average": 0.998777, "min": 0.993439}, "location": {"width": 294, "top": 317, "height": 37, "left": 157}, "words": "对驾驶和机械操作能力的影响:"}, {"probability": {"variance": 8e-06, "average": 0.998287, "min": 0.990115}, "location": {"width": 443, "top": 357, "height": 43, "left": 199}, "words": "没有进行本品对驾驶和机械操作能力影响的研究"}, {"probability": {"variance": 0, "average": 0.99961, "min": 0.996834}, "location": {"width": 879, "top": 392, "height": 55, "left": 200}, "words": "但考虑到头晕和嗜睡是阿戈美拉汀常见的不良反应,患者应注意对驾驶和操作机械能力的可能影"}, {"probability": {"variance": 0, "average": 0.978533, "min": 0.978533}, "location": {"width": 22, "top": 472, "height": 21, "left": 163}, "words": "响"}, {"probability": {"variance": 4e-06, "average": 0.998624, "min": 0.992453}, "location": {"width": 242, "top": 508, "height": 34, "left": 168}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0, "average": 0.999493, "min": 0.999017}, "location": {"width": 86, "top": 561, "height": 25, "left": 163}, "words": "生育能力"}, {"probability": {"variance": 8e-06, "average": 0.998339, "min": 0.985496}, "location": {"width": 808, "top": 582, "height": 53, "left": 205}, "words": "对大鼠和家兔进行的生殖研究显示阿戈美拉汀对生育能力没有影响(参见【药理毒理】)"}, {"probability": {"variance": 0, "average": 0.999154, "min": 0.998582}, "location": {"width": 44, "top": 656, "height": 24, "left": 164}, "words": "妊娠"}, {"probability": {"variance": 4e-06, "average": 0.998556, "min": 0.992821}, "location": {"width": 888, "top": 676, "height": 54, "left": 204}, "words": "阿戈美拉汀在妊娠妇女中的使用,尚无临床数据或数据有限(小于300例)。动物研究未发现对妊"}, {"probability": {"variance": 0.000146, "average": 0.996352, "min": 0.921145}, "location": {"width": 925, "top": 723, "height": 56, "left": 166}, "words": "娠,胚胎/胎儿发育,分娩或产后发育有直接或间接的损害(参见【药理毒理】)。作为预防措施,妊"}, {"probability": {"variance": 1.6e-05, "average": 0.99811, "min": 0.984048}, "location": {"width": 294, "top": 789, "height": 37, "left": 166}, "words": "娠期妇女应避免使用阿戈美拉汀"}, {"probability": {"variance": 0.000667, "average": 0.974121, "min": 0.948287}, "location": {"width": 38, "top": 848, "height": 24, "left": 170}, "words": "哺乳"}, {"probability": {"variance": 0.00481, "average": 0.981969, "min": 0.565562}, "location": {"width": 888, "top": 864, "height": 55, "left": 209}, "words": "目前尚不清楚阿戈美拉汀/代谢产物是否分泌入人类乳汁中。现有动物药效学/毒理学数据已证实阿"}, {"probability": {"variance": 0.006728, "average": 0.984561, "min": 0.438507}, "location": {"width": 930, "top": 912, "height": 56, "left": 168}, "words": "戈美拉汀代谢产物可分泌至大鼠的乳汁中(参见【药理毒理】)。不能排除对新生儿/婴儿的风险。必"}, {"probability": {"variance": 0.003145, "average": 0.989992, "min": 0.61886}, "location": {"width": 926, "top": 959, "height": 58, "left": 168}, "words": "须考虑哺乳带给婴儿的获益和治疗带给女性患者的获益后,再决定究竟是停止哺乳还是中止/放弃本品"}, {"probability": {"variance": 0, "average": 0.999969, "min": 0.999947}, "location": {"width": 44, "top": 1038, "height": 25, "left": 170}, "words": "治疗"}, {"probability": {"variance": 4e-06, "average": 0.998251, "min": 0.99503}, "location": {"width": 113, "top": 1080, "height": 29, "left": 179}, "words": "儿童用药】"}, {"probability": {"variance": 2.8e-05, "average": 0.997764, "min": 0.973784}, "location": {"width": 808, "top": 1104, "height": 54, "left": 219}, "words": "18岁以下儿童使用本品的安全性和有效性尚未建立,没有相关数据(参见【注意事项】)"}, {"probability": {"variance": 1.8e-05, "average": 0.996636, "min": 0.987581}, "location": {"width": 116, "top": 1174, "height": 31, "left": 179}, "words": "【老年用药】"}, {"probability": {"variance": 0.000641, "average": 0.992726, "min": 0.83268}, "location": {"width": 890, "top": 1198, "height": 54, "left": 214}, "words": "阿戈美拉汀(25-50mg/日)在老年抑郁症患者(<75岁)中的有效性和安全性已经建立。在≥75"}, {"probability": {"variance": 0.000215, "average": 0.995896, "min": 0.903006}, "location": {"width": 915, "top": 1245, "height": 57, "left": 174}, "words": "岁患者中的疗效尚无记载。因此,该年龄组患者不应使用阿戈美拉汀(见【注意事项】和【临床试验】)"}, {"probability": {"variance": 1.8e-05, "average": 0.997698, "min": 0.983577}, "location": {"width": 455, "top": 1308, "height": 42, "left": 176}, "words": "不需要针对年龄调整剂量(参见【药代动力学】)"}, {"probability": {"variance": 2.1e-05, "average": 0.995246, "min": 0.987548}, "location": {"width": 156, "top": 1366, "height": 28, "left": 183}, "words": "【药物相互作用】"}, {"probability": {"variance": 1e-06, "average": 0.999361, "min": 0.995195}, "location": {"width": 359, "top": 1407, "height": 38, "left": 176}, "words": "可能影响阿戈美拉汀的药物相互作用:"}, {"probability": {"variance": 2e-06, "average": 0.998541, "min": 0.997094}, "location": {"width": 109, "top": 1370, "height": 96, "left": 978}, "words": "限公"}, {"probability": {"variance": 0.000623, "average": 0.989827, "min": 0.825108}, "location": {"width": 887, "top": 1436, "height": 54, "left": 219}, "words": "阿戈美拉汀主要经细胞色素P4501A2(CYP1A2)(90%)和CYP2C919(10%)代谢。与这些酶"}, {"probability": {"variance": 1e-06, "average": 0.999273, "min": 0.995144}, "location": {"width": 568, "top": 1493, "height": 47, "left": 179}, "words": "有相互作用的药物可能会降低或提高阿戈美拉汀的生物利用度"}, {"probability": {"variance": 0.000755, "average": 0.993541, "min": 0.810774}, "location": {"width": 887, "top": 1532, "height": 53, "left": 220}, "words": "氟伏沙明是强效CYP1A2和中度CYP2C9抑制剂,可明显抑制阿戈美拉汀的代谢,使阿戈美拉汀"}], "language": 3}